[go: up one dir, main page]

MX2018013893A - Composicion topica estable. - Google Patents

Composicion topica estable.

Info

Publication number
MX2018013893A
MX2018013893A MX2018013893A MX2018013893A MX2018013893A MX 2018013893 A MX2018013893 A MX 2018013893A MX 2018013893 A MX2018013893 A MX 2018013893A MX 2018013893 A MX2018013893 A MX 2018013893A MX 2018013893 A MX2018013893 A MX 2018013893A
Authority
MX
Mexico
Prior art keywords
stable topical
topical composition
pharmaceutically acceptable
acceptable salts
composition
Prior art date
Application number
MX2018013893A
Other languages
English (en)
Inventor
Romero Medina Silvia
Maldonado Pérez Alejandro
Saúl Solorza Camacho Karim
De Jesús VELASCO HERNÁNDEZ Jose
Original Assignee
Productos Maver S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Productos Maver S A De C V filed Critical Productos Maver S A De C V
Priority to MX2018013893A priority Critical patent/MX2018013893A/es
Publication of MX2018013893A publication Critical patent/MX2018013893A/es
Priority to PCT/MX2019/000121 priority patent/WO2020101466A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención corresponde a una composición farmacéutica tópica estable que comprende betametasona o sus sales farmacéuticamente aceptables, indometacina o sus sales farmacéuticamente aceptables y un excipiente farmacéuticamente aceptable, la cual se caracteriza porque la composición está esencialmente libre de 4-ácido clorobenzoico; y 5-metoxi-2-metil-3-ácido indolacético.
MX2018013893A 2018-11-12 2018-11-12 Composicion topica estable. MX2018013893A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2018013893A MX2018013893A (es) 2018-11-12 2018-11-12 Composicion topica estable.
PCT/MX2019/000121 WO2020101466A1 (es) 2018-11-12 2019-11-12 Composición tópica estable

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2018013893A MX2018013893A (es) 2018-11-12 2018-11-12 Composicion topica estable.

Publications (1)

Publication Number Publication Date
MX2018013893A true MX2018013893A (es) 2019-05-13

Family

ID=67299010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013893A MX2018013893A (es) 2018-11-12 2018-11-12 Composicion topica estable.

Country Status (2)

Country Link
MX (1) MX2018013893A (es)
WO (1) WO2020101466A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE223202T1 (de) * 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
MXPA05010505A (es) * 2005-09-29 2007-03-28 Leopoldo Espinosa Abdala Forma farmaceutica que contiene metocarbamol, meloxicam y betametasona.
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
US9012402B1 (en) * 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation

Also Published As

Publication number Publication date
WO2020101466A1 (es) 2020-05-22

Similar Documents

Publication Publication Date Title
ZA201902053B (en) Pharmaceutical composition
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX380762B (es) Composiciones farmacéuticas que comprenden meloxicam.
CL2020002252A1 (es) Formulación oftálmica.
SA521421645B1 (ar) بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30
MX394588B (es) Composición farmacéutica.
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
WO2019073331A3 (en) Pharmaceutical compositions of apremilast
JOP20170137B1 (ar) صيغ قابلة للحقن متوازنة فسيولوجياً من فوسنيتوبيتانت
WO2019203771A3 (en) Solid oral pharmaceutical compositions comprising sitagliptin
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
ZA202203563B (en) Pediatric suspension formulation
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
MX2018013893A (es) Composicion topica estable.
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
WO2019132729A3 (ru) Фармацевтические композиции на основе ментилового эфира индометацина и его применение
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
TN2016000561A1 (en) Stabilized desmopressin
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
WO2020018034A3 (en) Oral pharmaceutical compositions comprising dpp-4 inhibitor